A Study Based on Health Insurance Data About the Treatment of Patients Who Have Been Newly Diagnosed With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Pulmonary Disease, Chronic Obstructive
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 17464
- Registration Number
- NCT04097223
- Locations
- 🇩🇪
Institute for pharmacoeconomics and pharmaceutical logistics e.V (IPAM), Wismar, Germany
A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT04093024
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇬🇷General Hospital of Thessaloniki "Ippokrateio", Thessaloniki, Greece
🇧🇷Serviços Medicos Respirar Sul Fluminense, Barra Mansa, Brazil
A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT04086121
- Locations
- 🇺🇸
The Indiana Clinical Trials Center, PC, Plainfield, Indiana, United States
🇯🇵Tokyo Medical University Hachioji Medical Center, Tokyo, Hachioji, Japan
🇺🇸Clinical Physiology Associates, Fort Myers, Florida, United States
TARA Working Prototype Engagement Evaluation: Feasibility Study
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Device: Digital Behaviour Change Intervention
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2020-09-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT04085302
- Locations
- 🇺🇸
Medullan, Somerville, Massachusetts, United States
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 65
- Registration Number
- NCT04065295
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 894416 in the Blood
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT04060719
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1
- First Posted Date
- 2019-08-16
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 52
- Registration Number
- NCT04059094
- Locations
- 🇧🇪
Brussels - UNIV UZ Brussel, Brussels, Belgium
🇫🇷HOP Arnaud de Villeneuve, Montpellier, France
🇫🇷HOP Robert Debré, Paris, France
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 152
- Registration Number
- NCT04015518
- Locations
- 🇯🇵
Shiga University of Medical Science Hospital, Shiga, Otsu, Japan
🇯🇵Teikyo University Hospital, Tokyo, Itabashi-ku, Japan
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2019-07-08
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1617
- Registration Number
- NCT04011475
- Locations
- 🇨🇳
Ditmanson Medical Foundation Chia - Yi Christian Hospital, Chia YI City, Taiwan
🇨🇳CGMH Chia YI, Chia YI City, Taiwan
🇨🇳CGMH Kaohsiung, Kaohsiung City, Taiwan
A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1323495 in the Blood
- First Posted Date
- 2019-07-08
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT04011241
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany